Research blood collection

OTHER4 trials

Sponsors

Abramson Cancer Center at Penn Medicine, Washington University School of Medicine, Memorial Sloan Kettering Cancer Center

Conditions

Alzheimer DiseaseBreast CancerDementiaMild Cognitive ImpairmentNon-Small Cell Lung CancerRenal Cell Carcinoma

Phase 2

Lenvatinib (LEN) in Combination With Pembrolizumab (KEYtruda) in Subjects With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma (The LENKYN Trial)

TerminatedNCT04267120

Washington University School of MedicineRenal Cell Carcinoma

Start: 2020-07-29End: 2024-09-01Updated: 2025-03-21

Using E-Nose Technology to Track Treatment Response in People With Non-Small Cell Lung Cancer

RecruitingNCT07218601

Memorial Sloan Kettering Cancer CenterNon-Small Cell Lung Cancer

Start: 2025-10-10End: 2027-10-01Target: 60Updated: 2026-03-23

Unknown Phase

PENN-Surveillance Markers of Utility for Recurrence After (Neo)Adjuvant Therapy for Breast Cancer

RecruitingNCT02732171

Abramson Cancer Center at Penn MedicineBreast Cancer

Start: 2016-04-30End: 2030-04-30Target: 600Updated: 2025-08-01

Study to Understand Novel Biomarkers in Researching Dementia

RecruitingNCT06547099

Washington University School of MedicineAlzheimer Disease, Dementia, Mild Cognitive Impairment

Start: 2024-08-14End: 2028-12-01Target: 1800Updated: 2026-01-16

Related Papers

Activity of Tivozanib in Non-clear Cell Renal Cell Carcinoma: Subgroup Analysis From a Phase II Randomized Discontinuation Trial

The Oncologist2023-06-143 citations